Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relacorilant + nab-paclitaxel in solid tumors
NCT02762981Phase 2Completed
- Sponsor
- Corcept Therapeutics
- Start
- May 2016
- Primary completion
- May 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of relacorilant in solid tumor, ovarian cancer, fallopian tube cancer (PFTC) and 3 more, sponsored by Corcept Therapeutics. Primary endpoint: Dose-limiting Toxicity. Started May 2016; status: completed.
02
Drugs
relacorilant
03
Conditions
solid tumorovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02762981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02762981.